Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Chugai

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Chugai's Japan sales performance.

ALK-Abello debuts its birch pollen allergy therapy in Germany

ALK-Abello debuts its birch pollen allergy therapy in Germany GlobalData said recently that the overall market for allergic rhinitis immunotherapies will reach $1.14bn by 2028, with the US and Japan contributing the lion’s share of growth based on

Roche’s flu drug Xofluza scores phase 3 primary endpoint

Roche’s flu drug Xofluza scores phase 3 primary endpoint The drug was discovered and developed by Shionogi, and is already approved in Japan, with Roche holding the marketing rights outside Japan and Taiwan.

AZ builds case for its COPD triple as it chases GSK’s Trelegy

AZ builds case for its COPD triple as it chases GSK’s Trelegy Breztri has its first approval in hand – in Japan – but isn’t due for regulatory decisions in Europe and the US until next year.

GSK files anaemia drug daprodustat in Japan, its first market

GSK files anaemia drug daprodustat in Japan, its first market class called vadadustat in late-stage clinical testing that is licensed to Mitsubishi Tanabe Pharma in some Asian markets including Japan. ... Astellas Pharma meanwhile has rights to roxadustat in Japan and Europe and has phase 3 trials on the go in

AbbVie scores FDA approval for arthritis treatment upadacitinib

AbbVie scores FDA approval for arthritis treatment upadacitinib Could find it difficult to live up to Humira

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...
Figure 1 Clarivate
The changing nature of approvals – what does the future hold?
The 2019 CMR International Pharmaceutical R&D Factbook...
Spotlight interview: 15 minutes on healthcare communications in gene therapy
Gavin Jones, Director of Rare Disease, OPEN Health takes 15 minutes to answer some key questions on healthcare communications in gene therapy...

Infographics